Short description
Action Pharma develops pharmaceutical products and treatment concepts for cardiovascular, inflammatory and acquired metabolic diseases.
Description
Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modified ÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
Last funding
Uh Ohhhh
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Aarhus, Midtjylland, Denmark, Europe
Founded on
January 1, 2000
Non-profit?
No
Acquired?
No
Employees count
1-10
Investors
Absolutely Noaccess, Noaccess, No Way, Noaccessforu, Cannot Access, Noaccessforu, Noaccessforu, Nopepepe
Sign in for full access